C

Cardiff Oncology
D

CRDF

3.65000
USD
0.06
(1.67%)
مغلق
حجم التداول
20,975
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
242,819,367
أصول ذات صلة
C
CELH
-0.010
(-0.02%)
46.350 USD
E
EXPI
-0.02500
(-0.26%)
9.49500 USD
M
MOGO
-0.40000
(-15.56%)
2.17000 USD
S
SENS
0.00700
(1.42%)
0.50140 USD
S
SNDL
0.02500
(2.01%)
1.27000 USD
V
VRA
0.08000
(3.20%)
2.58000 USD
I
IQST
-0.220
(-2.13%)
10.130 USD
المزيد
الأخبار المقالات

العنوان: Cardiff Oncology

القطاع: Healthcare
الصناعة: Biotechnology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.